首页> 外文期刊>Pakistan Heart Journal >GUIDELINE RECOMMENDED PHARMACOLOGICAL MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION, AT A TERTIARY CARE CARDIAC CENTRE, KARACHI PAKISTAN“ARE WE PRACTICING WHAT WE TEACH”?
【24h】

GUIDELINE RECOMMENDED PHARMACOLOGICAL MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION, AT A TERTIARY CARE CARDIAC CENTRE, KARACHI PAKISTAN“ARE WE PRACTICING WHAT WE TEACH”?

机译:指南建议在巴基斯坦卡拉奇市三心病中心的房颤患者进行药理学管理“我们在实践什么?”?

获取原文
           

摘要

Objective: To observe the practice of guideline recommend, pharmacological management of patients with Atrial fibrillation (AF), at tertiary care cardiac center. Methodology: It was a descriptive cross-sectional study of six months duration conducted in National Institute of Cardiovascular Diseases Karachi (NICVD) from April to October 2007.Two hundred indoor patients with AF were evaluated. Data was recorded and analyzed by SPSS version 16. Results: Majority of the patients with AF (76%), were <65 years of age. 46.5 % of patients had valvular heart disease. Rate controlling drugs were prescribed in 180 (90%) patients. Total of 88 (44%) patients received beta blocker, 83 (41.5%) patients received digoxin. In 19% of the patients with high risk for thromboemoblism, neither Aspirin nor Warfarin was prescribed. In 14 % of low risk patients, both Aspirin and Warfarin were advised. Conclusion: In contrast to western studies majority of our patients with AF were younger and almost half of them had valvular heart disease. Reasonable number of our patients with AF received guideline recommended pharmacological rate controlling therapy. Preventive pharmacological strategy for thromboembolic events was highly un-acceptable.
机译:目的:在三级保健心脏中心,观察指南推荐的实践,即房颤(AF)患者的药理管理。方法:该描述性横断面研究于2007年4月至10月在美国国立卡拉奇心血管疾病研究所(NICVD)进行,评估了200名室内AF患者。数据记录并通过SPSS版本16进行分析。结果:大多数AF患者(76%)年龄<65岁。 46.5%的患者患有瓣膜性心脏病。 180(90%)位患者开了速率控制药物。共有88名(44%)患者接受了β受体阻滞剂的治疗,83名(41.5%)患者接受了地高辛的治疗。在19%的血栓形成风险高的患者中,既不处方阿司匹林也不服用华法林。在14%的低风险患者中,建议使用阿司匹林和华法林。结论:与西方研究相反,我们大多数房颤患者较年轻,其中近一半患有瓣膜性心脏病。我们合理数量的房颤患者接受了指南推荐的药理速率控制疗法。血栓栓塞事件的预防性药理策略是高度不能接受的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号